Quarterly ResultApr 16, 2026, 07:46 AM
Abbott Q1 2026 Adj. EPS $1.15; Updates FY26 Guidance
AI Summary
Abbott Laboratories reported first-quarter 2026 adjusted diluted EPS of $1.15, a 6% increase, with sales growing 7.8% on a reported basis. The company completed its acquisition of Exact Sciences, establishing itself as a leader in oncology diagnostics. Abbott updated its full-year 2026 guidance, projecting comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58, which includes a $0.20 dilution from the Exact Sciences acquisition.
Key Highlights
- Q1 2026 adjusted diluted EPS was $1.15, reflecting 6% growth.
- First-quarter sales increased 7.8% reported and 3.7% comparable.
- Completed acquisition of Exact Sciences on March 23, 2026.
- Projects full-year 2026 comparable sales growth of 6.5% to 7.5%.
- Projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58.